Citations

Showing 10 of 108152 citations.

TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression
Jones, Dakota L. , Haak, Andrew J. , Caporarello, Nunzia , Choi, Kyoung Moo , Ye, Zhenqing, Yan, Huihuang , Varelas, Xaralabos , Ördög, Tamás , Ligresti, Giovanni , Tschumperlin, Daniel J. , Choi, Kyoung M, Varelas, Xaralabos , Caporarello, Nunzia

Mayo Clinic

Journal of Cell Science | September 16, 2019 | Volume: 132 | Issue: 20 | Pages: No page available

10.1242/jcs.233486 | PMID 31527052 Get It

ABSTRACT Tissue fibrosis is a chronic disease driven by persistent fibroblast activation that has recently been linked to epigenetic modifications. Here, we screened a small library of epigenetic small-molecule modulators to identify compounds capable of inhibiting or reversing TGFβ-mediated fibroblast activation. We identified pracinostat, an HDAC inhibitor, as a potent attenuator of lung fibroblast activation and confirmed its efficacy in patient-derived fibroblasts isolated from fibrotic lung tissue. Mechanistically, we found that HDAC-dependent transcriptional repression was an early and essential event in TGFβ-mediated fibroblast activation. Treatment of lung fibroblasts with pracinostat broadly attenuated TGFβ-mediated epigenetic repression and promoted fibroblast quiescence. We confirmed a specific role for HDAC-dependent histone deacetylation in the promoter region of the anti-fibrotic gene PPARGC1A (PGC1α) in response to TGFβ stimulation. Finally, we identified HDAC7 as a key factor whose siRNA-mediated knockdown attenuates fibroblast activation without altering global histone acetylation. Together, these results provide novel mechanistic insight into the essential role HDACs play in TGFβ-mediated fibroblast activation via targeted gene repression.
Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma
Qin, Yi , Wu, Chung Wah, Sawas, Tarek , Burger, Kelli N. , Yab, Tracy C. , Lidgard, Graham P. , Allawi, Hatim T. , Buttar, Navtej , Smyrk, Thomas C. , Iyer, Prasad G. , Katzka, David A. , Ahlquist, David A. , Wu, Chung W, Mahoney, Douglas W. , Buttar, Navtej S, Kisiel, John B , Qin, Y , Taylor, William R. , Sun, Zhifu , Kisiel, John B.

Mayo Clinic

Clinical Cancer Research | September 16, 2019 | Volume: 25 | Issue: 24 | Pages: 7396-7404

10.1158/1078-0432.ccr-19-0740 | PMID 31527170 Get It

Abstract Purpose: The burden of esophageal cancer continues to rise, and noninvasive screening tools are needed. Methylated DNA markers (MDM) assayed from plasma show promise in detection of other cancers. For esophageal cancer detection, we aimed to discover and validate MDMs in tissue, and determine their feasibility when assayed from plasma. Experimental Design: Whole-methylome sequencing was performed on DNA extracted from 37 tissues (28 EC; 9 normal esophagus) and 8 buffy coat samples. Top MDMs were validated by methylation specific PCR on tissue from 76 EC (41 adeno, 35 squamous cell) and 17 normal esophagus. Quantitative allele-specific real-time target and signal amplification was used to assay MDMs in plasma from 183 patients (85 EC, 98 controls). Recursive partitioning (rPART) identified MDM combinations predictive of esophageal cancer. Validation was performed in silico by bootstrapping. Results: From discovery, 23 candidate MDMs were selected for independent tissue validation; median area under the receiver operating curve (AUC) for individual MDMs was 0.93. Among 12 MDMs advanced to plasma testing, rPART modeling selected a 5 MDM panel (FER1L4, ZNF671, ST8SIA1, TBX15, ARHGEF4) which achieved an AUC of 0.93 (95% CI, 0.89–0.96) on best-fit and 0.81 (95% CI, 0.75–0.88) on cross-validation. At 91% specificity, the panel detected 74% of esophageal cancer overall, and 43%, 64%, 77%, and 92% of stages I, II, III, and IV, respectively. Discrimination was not affected by age, sex, smoking, or body mass index. Conclusions: Novel MDMs assayed from plasma detect esophageal cancer with moderate accuracy. Further optimization and clinical testing are warranted.
Seasonality of Bartonella henselae IgM and IgG Antibody Positivity Rates
Theel, Elitza S. , Ross, Teri K., Ross, Teri

Mayo Clinic

Journal of Clinical Microbiology | September 16, 2019 | Volume: 57 | Issue: 12 | Pages: No page available

10.1128/jcm.01263-19 | PMID 31533982 Get It

Electronic Cigarette Use among Survivors of Smoking-Related Cancers in the United States
Akinboro, Oladimeji , Nwabudike, Stanley Madu , Elias, Rawad , Balasire, Oluseyi, Ola, Olatunde , Nwabudike, Stanley , Ostroff, Jamie S , Elias, Rawad

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 16, 2019 | Volume: 28 | Issue: 12 | Pages: 2087-2094

10.1158/1055-9965.epi-19-0105 | PMID 31501150 Get It

Abstract Background: The prevalence of electronic cigarette (e-cigarette) use and its impact on smoking cessation among cancer survivors in the United States is largely unknown. We sought to estimate the prevalence of e-cigarette use and examine its associations with cigarette smoking and smoking quit attempts among smoking-related cancer survivors in the United States. Methods: We obtained data from the 2014–2017 annual cycles of the National Health Interview Survey for participants with self-reported history of smoking-related cancer(s). We calculated the prevalence of current e-cigarette use and utilized multinomial logistic regression in examining the independent association between e-cigarette use and cigarette smoking. Appropriate survey weights were applied in estimating the prevalence rates, relative risk ratios (RRR), ORs, and confidence intervals (CI). Results: Our sample comprised 3,162 smoking-related cancer survivors. The prevalence of current e-cigarette use was 3.18% (95% CI, 2.40–3.96). Current e-cigarette users were 83 times as likely as never users to be current cigarette smokers (RRR, 82.89; 95% CI, 16.54–415.37). Among those with a history of cigarette smoking, current e-cigarette users were 90% less likely to be former smokers (OR, 0.10; 95% CI, 0.05–0.18). No association was seen between current e-cigarette use and a smoking quit attempt in the prior year. Conclusions: E-cigarette use among cigarette ever smokers was associated with a lower likelihood of being a former smoker/having quit smoking, and e-cigarette use was not associated with smoking quit attempts. Impact: Our findings do not provide evidence that e-cigarette use facilitates smoking cessation among smoking-related cancer survivors.
Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors
Frantz, Robert P. , Hill, Jerrold, Lickert, Cassandra A., Wade, Rolin L. , Cole, Michele, Tsang, Yuen, Drake, William, Frantz, Robert P , Drake, William

Mayo Clinic

Pulmonary Circulation | September 16, 2019 | Volume: 10 | Issue: 1 | Pages: 1-11

10.1177/2045894019880086 | PMID 32274010 Get It

Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real‐world adherence to different pulmonary arterial hypertension drug classes are limited. This retrospective database analysis evaluated relationships between adherence, hospitalization, and healthcare costs in pulmonary arterial hypertension patients treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors. From the IQVIA Adjudicated Health Plan Database, patients with pulmonary arterial hypertension were identified based on diagnostic codes and prescriptions for endothelin receptor antagonists (ambrisentan, bosentan, macitentan) or phosphodiesterase type‐5 inhibitors (sildenafil, tadalafil) approved for pulmonary arterial hypertension. Patients were assigned to the class of their most recently initiated (index) pulmonary arterial hypertension therapy between 1 January 2009 and 30 June 2015. Medication adherence was measured by proportion of days covered; patients with proportion of days covered ≥80% were considered adherent. The proportion of adherent patients was higher for endothelin receptor antagonists (571/755; 75.6%) than for phosphodiesterase type‐5 inhibitors (970/1578; 61.5%; P < 0.0001). In both groups, hospitalizations declined as proportion of days covered increased. Among adherent patients, those on endothelin receptor antagonists had a significantly lower hospitalization rate than those on phosphodiesterase type‐5 inhibitors (23.1% versus 28.5%, P = 0. 0218), fewer hospitalizations (mean (standard deviation) 0.4 (0.8) versus 0.5 (0.9); P = 0.02), and mean hospitalization costs during the six‐month post‐index ($9510 versus $15,726, P = 0.0318). Increasing adherence reduced hospitalization risk more for endothelin receptor antagonists than for phosphodiesterase type‐5 inhibitors (hazard ratio 0.176 versus 0.549, P = 0.001). Rates and numbers of rehospitalizations within 30 days post‐discharge were similar between groups. Mean total costs were higher with endothelin receptor antagonists than phosphodiesterase type‐5 inhibitors in all patients ($91,328 versus $72,401, P = 0.0003) and in adherent patients ($88,867 versus $56,300, P < 0.0001), driven by higher drug costs.
MELD‐GRAIL‐Na: Glomerular Filtration Rate and Mortality on Liver‐Transplant Waiting List
Asrani, Sumeet K. , Jennings, Linda W. , Kim, W. Ray , Kamath, Patrick S. , Levitsky, Josh , Nadim, Mitra K. , Testa, Giuliano , Leise, Michael D. , Trotter, James F. , Klintmalm, Göran B. , Asrani, Sumeet K

Mayo Clinic

Hepatology | September 16, 2019 | Volume: 71 | Issue: 5 | Pages: 1766-1774

10.1002/hep.30932 | PMID 31523825 Get It

Background and Aims Among patients with cirrhosis awaiting liver transplantation, prediction of wait‐list (WL) mortality is adjudicated by the Model for End Stage Liver Disease–Sodium (MELD‐Na) score. Replacing serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) in the MELD‐Na score may improve prediction of WL mortality, especially for women and highest disease severity. Approach and Results We developed (2014) and validated (2015) a model incorporating eGFR using national data (n = 17,095) to predict WL mortality. Glomerular filtration rate (GFR) was estimated using the GFR assessment in liver disease (GRAIL) developed among patients with cirrhosis. Multivariate Cox proportional hazard analysis models were used to compare the predicted 90‐day WL mortality between MELD‐GRAIL‐Na (re‐estimated bilirubin, international normalized ratio [INR], sodium, and GRAIL) versus MELD‐Na. Within 3 months, 27.8% were transplanted, 4.3% died on the WL, and 4.7% were delisted for other reasons. GFR as estimated by GRAIL (hazard ratio [HR] 0.382, 95% confidence interval [CI] 0.344‐0.424) and the re‐estimated model MELD‐GRAIL‐Na (HR 1.212, 95% CI 1.199‐1.224) were significant predictors of mortality or being delisted on the WL within 3 months. MELD‐GRAIL‐Na was a better predictor of observed mortality at highest deciles of disease severity (≥ 27‐40). For a score of 32 or higher (observed mortality 0.68), predicted mortality was 0.67 (MELD‐GRAIL‐Na) and 0.51 (MELD‐Na). For women, a score of 32 or higher (observed mortality 0.67), the predicted mortality was 0.69 (MELD‐GRAIL‐Na) and 0.55 (MELD‐Na). In 2015, use of MELD‐GRAIL‐Na as compared with MELD‐Na resulted in reclassification of 16.7% (n = 672) of patients on the WL. Conclusion Incorporation of eGFR likely captures true GFR better than SCr, especially among women. Incorporation of MELD‐GRAIL‐Na instead of MELD‐Na may affect outcomes for 12%‐17% awaiting transplant and affect organ allocation.
Sarcopenia: A Time for Action. An SCWD Position Paper
Bauer, Jürgen M. , Morley, John E. , Schols, Annemie M.W.J. , Ferrucci, Luigi , Cruz‐Jentoft, Alfonso J. , Dent, Elsa , Crawford, Jeffrey A., Doehner, Wolfram , Jatoi, Aminah , Kalantar‐Zadeh, Kamyar, Landi, Francesco , Laviano, Alessandro , Muscaritoli, Maurizio , Prado, Carla M. , Strasser, Florian, Haehling, Stephan von , Kalantar-Zadeh, Kamyar , Ferrucci, Luigi , Baracos, Vickie E. , Heymsfield, Steven B. , Lainščak, Mitja , Mancuso, Michelangelo , Coats, Andrew J.S. , Anker, Stefan D. , Doehner, Wolfram , Kalantar-Zadeh, Kamyar

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | September 16, 2019 | Volume: 10 | Issue: 5 | Pages: 956-961

10.1002/jcsm.12483 | PMID 31523937 Get It

Abstract The term sarcopenia was introduced in 1988. The original definition was a “muscle loss” of the appendicular muscle mass in the older people as measured by dual energy x‐ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC‐F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease‐related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age‐related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age‐related and disease‐related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life‐long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.
Colonic Manifestations and Complications Are Relatively Under-Reported in Systemic Sclerosis: A Systematic Review
Brandler, Justin , Sweetser, Seth , Khoshbin, Katayoun, Babameto, Mary, Camilleri, Michael , Brandler, Justin B, Prokop, Larry J.

Mayo Clinic

American Journal of Gastroenterology | September 15, 2019 | Volume: 114 | Issue: 12 | Pages: 1847-1856

10.14309/ajg.0000000000000397 | PMID 31805016 Get It

OBJECTIVES: Although systemic sclerosis (SSc) is known to affect the gastrointestinal (GI) tract, most of the literature focuses on esophageal, small intestinal, or anorectal manifestations. There have been no reviews focused on large bowel SSc complications in over 30 years. The aim of this study is to perform a systematic review of colonic manifestations and complications of SSc. METHODS: An experienced librarian conducted a search of databases, including English and Spanish articles. The search used keywords including “systemic sclerosis,” “scleroderma,” and “colon.” A systematic review was performed using Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Case reports/series were screened for validity by adapting from criteria published elsewhere. RESULTS: Of 1,890 articles, 74 met selection criteria. Fifty-nine of the 77 articles were case reports/series. The most common article topics on colonic SSc complications were constipation/dysmotility (15), colonic volvulus (8), inflammatory bowel disease (7), microscopic colitis (6), megacolon (6), and telangiectasia (6). Colonic manifestations constituted 24% of articles on GI complications of SSc. There were a total of 85 cases (84% women, with a median age of onset of colon complication of 52 years). Limited cutaneous SSc phenotype (65.6%) was more common than diffuse (26.2%). Patients frequently had poor outcomes with high mortality related to colonic complications (27%). Recent studies explore contemporary topics such as the microbiome in SSc and prucalopride for chronic constipation in SSc. DISCUSSION: Colonic complications comprise a large proportion of the published reports on GI symptoms afflicting patients with SSc and require raised diagnostic suspicion and deliberate action to avoid potentially serious complications including death.
Attenuated activation of the unfolded protein response following exercise in skeletal muscle of older adults
Hart, Corey R., Ryan, Zachary C. , Pfaffenbach, Kyle T., Dasari, Surendra , Parvizi, Mojtaba, Lalia, Antigoni Z., Lanza, Ian R. , Lanza, Ian R

Mayo Clinic

Aging | September 15, 2019 | Volume: 11 | Issue: 18 | Pages: 7587-7604

10.18632/aging.102273 | PMID 31525732 Get It

Reducing Barriers for Women in Plastic Surgery: What Should We Pursue?
Huayllani, María T. , Eells, Annica C. , Khan, Nawal , Rinker, Brian, Forte, Antonio J. , Forte, Antonio Jorge

Mayo Clinic

Plastic & Reconstructive Surgery | September 14, 2019 | Volume: 144 | Issue: 6 | Pages: 1132e-1133e

10.1097/prs.0000000000006286 | PMID 31764706 Get It